Clearside Biomedical, Inc.

Informe acción NasdaqGM:CLSD

Capitalización de mercado: US$75.5m

Clearside Biomedical Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Clearside Biomedical has been growing earnings at an average annual rate of 3.5%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 12.2% per year.

Información clave

3.5%

Tasa de crecimiento de los beneficios

22.5%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals 6.0%
Tasa de crecimiento de los ingresos12.2%
Rentabilidad financieran/a
Margen neto-444.7%
Próxima actualización de resultados12 Nov 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Nov 06
Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate

Jun 24
We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate

Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Nov 12
Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)

Aug 11
Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)

Clearside Biomedical Q2 2022 Earnings Preview

Aug 08

Clearside Biomedical: A Pivotal 2022 Ahead

Apr 13

Clearside's Safety Data In Wet AMD And Emphasis On SCS Microinjector Make It Great Speculative Play

Dec 22

Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business

Sep 30
Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business

Clearside's Value Proposition Is Far From Clear

Aug 07

We Think Clearside Biomedical (NASDAQ:CLSD) Can Easily Afford To Drive Business Growth

Jun 17
We Think Clearside Biomedical (NASDAQ:CLSD) Can Easily Afford To Drive Business Growth

Clearside Biomedical climbs after positive results from early-stage wet AMD trial

Jun 15

Clearside Biomedical resubmits eye treatment XIPERE NDA

May 03

If You Had Bought Clearside Biomedical (NASDAQ:CLSD) Shares A Year Ago You'd Have Earned 45% Returns

Feb 16
If You Had Bought Clearside Biomedical (NASDAQ:CLSD) Shares A Year Ago You'd Have Earned 45% Returns

Desglose de ingresos y gastos

Cómo gana y gasta dinero Clearside Biomedical. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

NasdaqGM:CLSD Ingresos, gastos y beneficios (USD Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
30 Jun 248-331122
31 Mar 248-351222
31 Dec 238-321221
30 Sep 232-371220
30 Jun 232-361219
31 Mar 231-351120
31 Dec 221-331220
30 Sep 2227-51218
30 Jun 2229-21219
31 Mar 223001218
31 Dec 213001219
30 Sep 214-251119
30 Jun 214-231118
31 Mar 214-231117
31 Dec 208-181115
30 Sep 2010-141212
30 Jun 207-18139
31 Mar 206-18169
31 Dec 192-311716
30 Sep 190-491732
30 Jun 190-671752
31 Mar 190-821666
31 Dec 180-831568
30 Sep 180-781365
30 Jun 180-721161
31 Mar 180-651055
31 Dec 170-591049
30 Sep 170-521042
30 Jun 170-39930
31 Mar 170-31822
31 Dec 161-26619
30 Sep 161-21516
30 Jun 161-19515
31 Mar 161-19713
31 Dec 150-18711
30 Sep 150-1569
30 Jun 150-1569
31 Mar 150-1248
31 Dec 140-1037
30 Sep 140-936
30 Jun 140-835
31 Mar 140-825

Ingresos de calidad: CLSD is currently unprofitable.

Margen de beneficios creciente: CLSD is currently unprofitable.


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: CLSD is unprofitable, but has reduced losses over the past 5 years at a rate of 3.5% per year.

Acelerando crecimiento: Unable to compare CLSD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Beneficios vs. Industria: CLSD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).


Rentabilidad financiera

Alta ROE: CLSD's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado